Glial phenotype modulators

Neuroinflammation is an important component of many neuroinflammatory and neurodegenerative diseases. Microglia and astrocytes play a key role in neuroinflammation. Activated glial cells under neuroinflammatory condition produce proinflammatory cytokines, chemokines, nitric oxide (NO), and other neurotoxic mediators. Thus, it has been conventionally thought that the inhibition of such glial activation might be an effective neuroprotective strategy under inflammatory or degenerative disease conditions in the central nervous system (CNS). However, recent studies indicated that activated glia could adopt either neuroprotective or neurotoxic phenotype depending on instigating stimuli present in the given microenvironment [1]. Lipopolysaccharide (LPS) and interferon-gamma are representative stimuli that induce neurotoxic phenotype, while interleukin-4 and interleukin-10 mainly induce neuroprotective one. Although it was initially believed that functional dichotomy such as M1 and M2 phenotypes exists representing two different functional phenotypes of microglia, it is now widely accepted that such classification is an oversimplified view, and that activated glia show a continuum of the two extreme functional phenotypes. Therefore, modulation of glial phenotypes, rather than mere blockade of glial activation, appears to be more desirable to regain the glial balance that was lost in various disease conditions. Especially, small-moleculebased approaches to switching glial phenotypes seem to be quite attractive, because small-molecule drugs have higher chances of crossing blood-brain barrier, thereby being effective in the CNS. In a recent study by Song et al. [2], a phenotypic screen of small-molecule library using microglia cellbased assay was performed to search for glial phenotype modulators (GPM) (Figure 1). This screen identified a hit compound containing N-carbamoylated urethane moiety, which inhibited LPS-induced NO production in microglia. The small-molecule GPM compound inhibited proinflammatory cytokines and inducible nitric oxide synthase in LPS-stimulated microglia, and potentiated interleukin-4-induced arginase-1 expression, indicating that the GPM induces switching of microglial phenotype toward to an anti-inflammatory state. Peroxisome proliferator-activated receptor (PPAR)-γ was identified as a molecular target of the compound. The GPM specifically activated PPAR-γ, but not PPAR-δ or -α, in the PPAR response element reporter assay, thereby assuring that PPAR-γ is the authentic target protein of the GPM. Genetic and pharmacological inhibition of PPAR-γ attenuated phenotype switching effects of the GPM, further confirming the role of PPAR-γ as the molecular target of the GPM. When the study was extended to astrocytes, Song et al. found that the GPM similarly inhibited proinflammatory TNF-α and NO production, while enhancing the expression of anti-inflammatory genes, such as arginase-1 and Ym-1. These results suggested that the GPM induces an anti-inflammatory phenotypic switch in astrocytes as well. The effect of the GPM on glial activation was also tested in vivo using an LPS-induced mouse neuroinflammation model. In a pharmacokinetic study, the brain distribution of the GPM after intraperitoneal administration with relatively long half-life time was demonstrated. A quantitative analysis of the different brain regions revealed that the intraperitoneally administered GPM effectively blocked the systemic LPS-mediated microglial hyper-activation in cortex, hippocampus, and substantia nigra, suggesting a therapeutic potential for neuroinflammatory diseases. Editorial